[Form 4] BOSTON SCIENTIFIC CORP Insider Trading Activity

Rhea-AI Filing Summary

Boston Scientific director Edward J. Ludwig received an annual equity award in the form of restricted stock. On the grant date, he acquired 3,800 shares of common stock at no cash cost as a grant or award. The award reflects a value of $215,000 divided by the closing price of the common stock on the grant date. These restricted shares vest in full at the next annual meeting of stockholders. Following this grant, Ludwig directly holds 21,779 shares of Boston Scientific common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LUDWIG EDWARD J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,800	$0.00	--

Holdings After Transaction: Common Stock — 21,779 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restricted shares granted: 3,800 shares Grant value: $215,000 Shares held after grant: 21,779 shares +2 more

5 metrics

Restricted shares granted 3,800 shares Annual equity award of common stock

Grant value $215,000 Equity award value divided by grant-date closing price

Shares held after grant 21,779 shares Total direct holdings following this transaction

Transaction price per share $0.0000 Grant/award, no cash paid by insider

Transaction date 2026-05-07 Date of restricted stock grant

Key Terms

restricted stock, annual equity award, closing price, grant, award, or other acquisition

4 terms

restricted stock financial

"Annual equity award in the form of restricted stock vesting in full upon the next annual meeting"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

annual equity award financial

"Annual equity award in the form of restricted stock vesting in full upon the next annual meeting"

closing price financial

"Reflects a value of $215,000 divided by the closing price of common stock on the date of grant"

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LUDWIG EDWARD J

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MASSACHUSETTS 01752-1234

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026		A(1)		3,800	A	$0.0000	21,779	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Boston Scientific (BSX) report for Edward J. Ludwig?

Boston Scientific reported that director Edward J. Ludwig received a grant of 3,800 shares of restricted common stock. This annual equity award was issued at no cash cost as compensation and is tied to a disclosed grant-date value and vesting schedule.

How large is Edward J. Ludwig’s new Boston Scientific (BSX) equity award?

Edward J. Ludwig received an equity award valued at $215,000, represented by 3,800 restricted shares of Boston Scientific common stock. The number of shares comes from dividing that dollar value by the stock’s closing price on the grant date.

When do Edward J. Ludwig’s new Boston Scientific (BSX) restricted shares vest?

The 3,800 restricted shares granted to Edward J. Ludwig vest in full at the next annual meeting of stockholders. Until that meeting occurs, the award remains unvested but reflects his compensation as a company director.

Did Edward J. Ludwig buy or sell any Boston Scientific (BSX) shares in this filing?

The filing shows no open-market purchases or sales by Edward J. Ludwig. Instead, he acquired 3,800 shares through an equity grant classified as a grant, award, or other acquisition, rather than a traditional market transaction.

How many Boston Scientific (BSX) shares does Edward J. Ludwig hold after this grant?

After receiving the 3,800-share restricted stock grant, Edward J. Ludwig directly holds 21,779 shares of Boston Scientific common stock. This total includes his existing holdings plus the new award reported in the insider transaction.